Isoprenoids and protein prenylation

implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease

Angela Jeong, Kiall Francis Suazo, W. Gibson Wood, Mark D. Distefano, Ling Li

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The mevalonate–isoprenoid–cholesterol biosynthesis pathway plays a key role in human health and disease. The importance of this pathway is underscored by the discovery that two major isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are required to modify an array of proteins through a process known as protein prenylation, catalyzed by prenyltransferases. The lipophilic prenyl group facilitates the anchoring of proteins in cell membranes, mediating protein–protein interactions and signal transduction. Numerous essential intracellular proteins undergo prenylation, including most members of the small GTPase superfamily as well as heterotrimeric G proteins and nuclear lamins, and are involved in regulating a plethora of cellular processes and functions. Dysregulation of isoprenoids and protein prenylation is implicated in various disorders, including cardiovascular and cerebrovascular diseases, cancers, bone diseases, infectious diseases, progeria, and neurodegenerative diseases including Alzheimer’s disease (AD). Therefore, isoprenoids and/or prenyltransferases have emerged as attractive targets for developing therapeutic agents. Here, we provide a general overview of isoprenoid synthesis, the process of protein prenylation and the complexity of prenylated proteins, and pharmacological agents that regulate isoprenoids and protein prenylation. Recent findings that connect isoprenoids/protein prenylation with AD are summarized and potential applications of new prenylomic technologies for uncovering the role of prenylated proteins in the pathogenesis of AD are discussed.

Original languageEnglish (US)
Pages (from-to)279-310
Number of pages32
JournalCritical Reviews in Biochemistry and Molecular Biology
Volume53
Issue number3
DOIs
StatePublished - May 4 2018

Fingerprint

Protein Prenylation
Terpenes
Alzheimer Disease
Dimethylallyltranstransferase
Proteins
Therapeutics
Progeria
Lamins
Cerebrovascular Disorders
Heterotrimeric GTP-Binding Proteins
Bone Neoplasms
Protein Array Analysis
Monomeric GTP-Binding Proteins
Bone Diseases
Neurodegenerative Diseases
Communicable Diseases
Signal Transduction
Neurodegenerative diseases
Membrane Proteins
Cardiovascular Diseases

Keywords

  • Alzheimer’s disease
  • Isoprenoids
  • bisphosphonates
  • prenylomics
  • prenyltransferase inhibitors
  • protein prenylation
  • small GTPases
  • statins

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

Cite this

Isoprenoids and protein prenylation : implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease. / Jeong, Angela; Suazo, Kiall Francis; Wood, W. Gibson; Distefano, Mark D.; Li, Ling.

In: Critical Reviews in Biochemistry and Molecular Biology, Vol. 53, No. 3, 04.05.2018, p. 279-310.

Research output: Contribution to journalReview article

@article{1275a18b8fff498e97b210c7fda75d47,
title = "Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease",
abstract = "The mevalonate–isoprenoid–cholesterol biosynthesis pathway plays a key role in human health and disease. The importance of this pathway is underscored by the discovery that two major isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are required to modify an array of proteins through a process known as protein prenylation, catalyzed by prenyltransferases. The lipophilic prenyl group facilitates the anchoring of proteins in cell membranes, mediating protein–protein interactions and signal transduction. Numerous essential intracellular proteins undergo prenylation, including most members of the small GTPase superfamily as well as heterotrimeric G proteins and nuclear lamins, and are involved in regulating a plethora of cellular processes and functions. Dysregulation of isoprenoids and protein prenylation is implicated in various disorders, including cardiovascular and cerebrovascular diseases, cancers, bone diseases, infectious diseases, progeria, and neurodegenerative diseases including Alzheimer’s disease (AD). Therefore, isoprenoids and/or prenyltransferases have emerged as attractive targets for developing therapeutic agents. Here, we provide a general overview of isoprenoid synthesis, the process of protein prenylation and the complexity of prenylated proteins, and pharmacological agents that regulate isoprenoids and protein prenylation. Recent findings that connect isoprenoids/protein prenylation with AD are summarized and potential applications of new prenylomic technologies for uncovering the role of prenylated proteins in the pathogenesis of AD are discussed.",
keywords = "Alzheimer’s disease, Isoprenoids, bisphosphonates, prenylomics, prenyltransferase inhibitors, protein prenylation, small GTPases, statins",
author = "Angela Jeong and Suazo, {Kiall Francis} and Wood, {W. Gibson} and Distefano, {Mark D.} and Ling Li",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/10409238.2018.1458070",
language = "English (US)",
volume = "53",
pages = "279--310",
journal = "Critical Reviews in Biochemistry and Molecular Biology",
issn = "1040-9238",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Isoprenoids and protein prenylation

T2 - implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease

AU - Jeong, Angela

AU - Suazo, Kiall Francis

AU - Wood, W. Gibson

AU - Distefano, Mark D.

AU - Li, Ling

PY - 2018/5/4

Y1 - 2018/5/4

N2 - The mevalonate–isoprenoid–cholesterol biosynthesis pathway plays a key role in human health and disease. The importance of this pathway is underscored by the discovery that two major isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are required to modify an array of proteins through a process known as protein prenylation, catalyzed by prenyltransferases. The lipophilic prenyl group facilitates the anchoring of proteins in cell membranes, mediating protein–protein interactions and signal transduction. Numerous essential intracellular proteins undergo prenylation, including most members of the small GTPase superfamily as well as heterotrimeric G proteins and nuclear lamins, and are involved in regulating a plethora of cellular processes and functions. Dysregulation of isoprenoids and protein prenylation is implicated in various disorders, including cardiovascular and cerebrovascular diseases, cancers, bone diseases, infectious diseases, progeria, and neurodegenerative diseases including Alzheimer’s disease (AD). Therefore, isoprenoids and/or prenyltransferases have emerged as attractive targets for developing therapeutic agents. Here, we provide a general overview of isoprenoid synthesis, the process of protein prenylation and the complexity of prenylated proteins, and pharmacological agents that regulate isoprenoids and protein prenylation. Recent findings that connect isoprenoids/protein prenylation with AD are summarized and potential applications of new prenylomic technologies for uncovering the role of prenylated proteins in the pathogenesis of AD are discussed.

AB - The mevalonate–isoprenoid–cholesterol biosynthesis pathway plays a key role in human health and disease. The importance of this pathway is underscored by the discovery that two major isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are required to modify an array of proteins through a process known as protein prenylation, catalyzed by prenyltransferases. The lipophilic prenyl group facilitates the anchoring of proteins in cell membranes, mediating protein–protein interactions and signal transduction. Numerous essential intracellular proteins undergo prenylation, including most members of the small GTPase superfamily as well as heterotrimeric G proteins and nuclear lamins, and are involved in regulating a plethora of cellular processes and functions. Dysregulation of isoprenoids and protein prenylation is implicated in various disorders, including cardiovascular and cerebrovascular diseases, cancers, bone diseases, infectious diseases, progeria, and neurodegenerative diseases including Alzheimer’s disease (AD). Therefore, isoprenoids and/or prenyltransferases have emerged as attractive targets for developing therapeutic agents. Here, we provide a general overview of isoprenoid synthesis, the process of protein prenylation and the complexity of prenylated proteins, and pharmacological agents that regulate isoprenoids and protein prenylation. Recent findings that connect isoprenoids/protein prenylation with AD are summarized and potential applications of new prenylomic technologies for uncovering the role of prenylated proteins in the pathogenesis of AD are discussed.

KW - Alzheimer’s disease

KW - Isoprenoids

KW - bisphosphonates

KW - prenylomics

KW - prenyltransferase inhibitors

KW - protein prenylation

KW - small GTPases

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=85046539075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046539075&partnerID=8YFLogxK

U2 - 10.1080/10409238.2018.1458070

DO - 10.1080/10409238.2018.1458070

M3 - Review article

VL - 53

SP - 279

EP - 310

JO - Critical Reviews in Biochemistry and Molecular Biology

JF - Critical Reviews in Biochemistry and Molecular Biology

SN - 1040-9238

IS - 3

ER -